Evergreen Theragnostics
AcquiredImproving the options for cancer patients through theragnostic radiopharmaceuticals
- Headquarters
- Springfield, New Jersey
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- evergreentgn.com
- Total Funding
- $202.0M
- Last Round
- $19.0M Series AJun 2026
- Rounds
- 7
About
Evergreen Theragnostics is a radiopharmaceutical CDMO specializing in theragnostic solutions for cancer treatment. The company develops and manufactures targeted radiopharmaceuticals including Gallium-68 DOTATOC diagnostic kits and targeted alpha therapy agents. Acquired by Lantheus in 2025.
Summary
Evergreen Theragnostics is a Biotech company based in Springfield, United States, founded in 2019. It has raised $202.0M in total across 7 rounds, most recently a $19.0M Series A round in Jun 2026. Investors include RA Capital Management, LIFTT and Private Investors.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jun 2026
Sign up to see all 8 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...